BioCryst Pharmaceuticals | BCRX - Market Capitalization


BioCryst Pharmaceuticals reported $1.89B in Market Capitalization this May of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
BioCryst Pharmaceuticals USD 1.66B 64M Dec/2025
Chugai Pharma JPY 14.46T 617.89B Mar/2026
Daiichi Sankyo JPY 6.34T 62.51B Dec/2025
DBV Technologies USD 274M 17M Sep/2025
Enanta Pharmaceuticals USD 122M 98M Dec/2024
Gilead Sciences USD 152.28B 14.55B Dec/2025
GlaxoSmithKline GBP 83.8B 9.44B Mar/2026
Incyte USD 21.73B 3B May/2026
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
Karyopharm Therapeutics USD 956M 821M May/2026
Neurocrine Biosciences USD 13.34B 800M May/2026
Novavax USD 1.09B 316M Dec/2025
PTC Therapeutics USD 6.1B 1.22B Dec/2025
Regeneron Pharmaceuticals USD 81.68B 560M Mar/2026
Roche Holding CHF 266.34B 55.46B Dec/2025
Sarepta Therapeutics USD 2.26B 238M Dec/2025
Ultragenyx Pharmaceutical USD 2.04B 176M May/2026
Vertex Pharmaceuticals USD 111.03B 2.55B May/2026